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Abstract
Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after
chemotherapy and targeted therapy and is now established as a potent and effective treatment option across
several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-
programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged
increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune
targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds
of research institutes across the globe. The potential use of these different immunotherapeutic options in various
combinations with one another and with other treatment modalities is an area of particular promise. The third
Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in
immunotherapy across various cancer types and is summarised in this report.
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Background
Immunotherapy represents the third important wave in
the history of the systemic treatment of cancer, following
on from the advent of chemotherapy in the 1940’s and
targeted therapy in the late 1990’s. Since its first clinical
application as Coley's toxins towards the end of the 19th
century, after a postsurgical infection was observed to
result in spontaneous tumour regression, the field of im-
munotherapy has finally come of age and is now established
as a potent and effective treatment option across several
cancer types. The clinical success of immune checkpoint
blockade with anti-cytotoxic T-lymphocyte-associated
antigen (CTLA)-4 and anti-programmed death (PD)-1/
PD-ligand (L)1 agents in melanoma and other cancers has
encouraged increasing focus on the development of other
immunotherapies, particularly monoclonal antibodies with
other immune targets, adoptive cell transfer and vaccines.
Indeed, it has been estimated that there are over 3000
immuno-oncology trials ongoing, targeting hundreds of
disease and immune pathways and involving hundreds of
research institutes across the globe. The potential use of
these different immunotherapeutic options in various
combinations with one another and with other treat-
ment modalities is an area of particular promise. This
report summarizes the recent advances in immuno-
therapy across various cancer types as discussed
during the third Immunotherapy Bridge meeting
(29-30 November, 2017, Naples, Italy).
Cumulative suppression index, cancer vaccines
and a strategy to develop combination
immunotherapy with T cell agonists
Evaluation of T lymphocyte frequency provides prognos-
tic information for patients with cancer. Moreover, the
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location and relative positions between immune popula-
tions (i.e. distance of T regulatory cells [Tregs] and
PD-L1 to CD8 T cells) are important factors in under-
standing their function in a complex environment and
this information can enhance the prognostic power of
CD8+ cells. Integrating this information into a cumula-
tive suppression index (CSI) can increase correlation
with overall survival (OS) and incorporating tumour ex-
pression levels of antigen-processing machinery compo-
nents can further improve prognostic power [1]. If
validated, CSI may be useful in stratifying patients for
clinical trials as well as directing therapy choices.
Autophagy is a cellular process in which portions of the
cytoplasm are sequestered by double membrane vesicles
termed autophagosomes and is essential for efficient
cross-presentation and subsequent induction of tumour
immunity. Cross-presentation is significantly inhibited
when autophagy is blocked and increased when autophagy
is promoted. Isolated autophagosome-containing vesicles,
known as Dribbles can serve as a potent antigen source
and have shown cross-protection against related tumours
and efficacy against established tumours in preclinical
studies [2]. Efficacy may be via presentation of short-lived
proteins (SLiPs) and defective ribosomal products (DRiPs)
normally not cross-presented by antigen-presenting cells.
DPV-001 is a DC-targeted (CLEC9A) microvesicle vaccine
derived from an adenocarcinoma and a mixed histology
cell line that contains multiple toll-like receptor (TLR) ag-
onists and >130 potential non-small cell lung cancer
(NSCLC) antigens, many as prospective altered-peptide li-
gands. In a phase II trial, DPV-001 alone or with
granulocyte-macrophage colony-stimulating factor
(GM-CSF) or imiquimod for adjuvant treatment of stage
III NSCLC was tolerable and induced or boosted IgG anti-
bodies to TAAs (tumour-associated antigens) [3].
DPV-001 also expanded populations of T cells with in-
creases in CD4 T cells similar to those observed in pa-
tients receiving anti-CTLA-4 ipilimumab [4].
DPV-001 is also being evaluated in combination with
anti-OX40 agonists. OX-40 increases T cell expansion
and cytokine production and OX-40 signalling also
controls regulatory T cell differentiation and suppressive
function [5]. Although OX-40 agonists enhance anti-tumour
immunity in immunogenic tumours, poorly immunogenic
tumours are less responsive. Combining vaccine strategies
that prime tumour-specific T cells with OX-40 agonists
could sustain anti-tumour responses.
Development of cancer vaccines for
hepatocellular carcinoma
Hepatocellular carcinoma (HCC) accounts for about 6%
of all new cancers worldwide and represents the third
most common cause of cancer-related death. The overall
prognosis for patients with HCC is poor, especially in
patients with more advanced disease stage in which
available treatments (e.g. sorafenib, an anti-vascular
endothelial growth factor inhibitor) have limited efficacy.
Immunotherapy-based strategies may represent a novel
and effective tool for patients with HCC, although previ-
ous efforts have had only mixed success.
One potential immunotherapeutic approach in HCC is
the development of peptide vaccines. Tumour-associated
antigens (TAAs) are self-derived proteins rendered im-
munogenic in tumours by aberrant expression. In HCC
patients, several TAAs can spontaneously induce CD8+
T cell responses including alpha fetoprotein (AFP),
glypican-3 (GPC-3), and melanoma-associated gene-A1
(MAGE-A1). The first HCC vaccine clinical trial was
based on CD8+ T cell epitopes specific for AFP and
showed T cell responses in vaccinated subjects [6]. The
same group performed a subsequent phase I/II trial ad-
ministering AFP epitopes presented by autologous den-
dritic cells (DCs) loaded ex vivo. This, however, only
produced transient CD8+ T cell responses, possibly due
to the lack of CD4+ help [7, 8]. To increase the number
of TAAs targeted by the immune response, vaccines
based on autologous DCs pulsed ex vivo with a lysate of
the autologous tumour [9] or hepatoblastoma cell line
HepG2 [10, 11] were evaluated, but achieved only lim-
ited improvements in clinical outcomes. Other trials, in-
cluding low-dose cyclophosphamide treatment followed
by a telomerase peptide (GV1001) vaccination [12],
MRP3-derived peptide (MRP3765) [13] and adjuvant
GPC-3 peptide [14] vaccine have also had mixed results.
The main limiting factors in HCC vaccine develop-
ment is that the TAAs used in clinical trials are limited
in number and not HCC-specific, together with the in-
herent intra-hepatic immunosuppressive environment.
The current ongoing EU-funded HepaVAC project is de-
veloping a new concept of therapeutic cancer vaccines
for HCC, aimed at overcoming the limitations of previ-
ous efforts (www.hepavac.eu). The main goal of Hepa-
VAC is to develop a novel therapeutic cancer vaccine to
improve clinical outcome after standard therapy. The
HepaVac vaccine consists of an ‘off-the-shelf ’ vaccine
comprising 18 newly identified MHC-I and II
tumour-associated peptides (TUMAPs) naturally proc-
essed and presented on primary tumour tissues from
HCC patients (HLA peptidome), for the induction of
tumour-specific CD4+ T helper cell and cytotoxic CD8+
lymphocyte effector and memory immune responses. In
a subgroup of enrolled patients, an actively personalised
vaccine (APVAC) will be administered during the treat-
ment as boosting antigen, based on patient-specific mu-
tated and naturally processed and presented peptides.
Both vaccines will be combined with a novel and potent
RNA-based immunomodulator [15]. As part of this ini-
tiative, a first-in-man, open-label, multicentre European
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phase I/II clinical trial (HepaVac-101; NCT03203005)
will assess the safety, tolerability and immunogenicity of
the vaccine. To date, five of six study sites have initiated
the trial and started screening patients.
A related EU-supported project is HEPAMUT, the pri-
mary aim of which is the identification and immuno-
logical validation of mutated neoantigens specific to
HCC (www.hepamut.eu). This project will involve evalu-
ating the HCC mutanome and predicting the presenta-
tion of neoepitopes by HLA-A2*01 allele, assessing the
frequency of specific T cells to such mutant epitopes in
HCC patients, and validating the immunogenicity of
neoepitopes in HLA-transgenic mice and their thera-
peutic effect in a humanised patient-derived xenograft
mouse model.
One important consideration in the identification of
neoantigens is the distinction between true and false
neo-antigens. Mutated peptides may represent non-self
neoantigens that are exclusively presented on tumour
cells and are not affected by central T cell tolerance. In
an analysis of tumour tissue from patients with melan-
oma treated with anti-CTLA-4 ipilimumab or tremeli-
mumab, whole-exome sequencing revealed a neoantigen
landscape specifically present in tumours with a strong
response to CTLA-4 blockade, with the presence of spe-
cific tumour neoantigens shared by patients with
long-term clinical benefit but absent in patients with
minimal or no benefit [16]. Data suggest that the neoepi-
topes in patients with strong clinical benefit from
CTLA-4 blockade may resemble epitopes from patho-
gens that T cells are likely to recognise. Thus, patients
with neoantigens similar to pathogen antigens are more
likely to respond to treatment. False predictive neoanti-
gens have similar predicted antigenicity to the corre-
sponding wild-type epitope and may be less likely to
confer benefit.
Novel combinatorial immunotherapies with PD-1
blockade from the bench into the clinic
Anti-PD-1 antibodies represent a potent therapy of
melanoma and other solid tumours. However, resist-
ance to PD-1 blockade is an ongoing problem and
various other strategies to target tumour-intrinsic and
tumour-extrinsic mechanisms driving anti-tumour T
cell dysfunction are being assessed (Fig. 1). Two tar-
gets for immune checkpoint blockade are T cell im-
munoglobulin domain and mucin domain-3 (Tim-3)
and T cell Immunoglobulin and ITIM domain
(TIGIT). Dual Tim-3 and PD-1 expression is associ-
ated with enhanced tumour antigen-specific CD8+ T
cell dysfunction in melanoma patients [17]. TIGIT is also
upregulated on tumour antigen-specific CD8+ T cells and
CD8+ tumour-infiltrating lymphocytes (TILs) from pa-
tients with melanoma. These TIGIT-expressing CD8+ T
cells often co-express PD-1 [18]. TIGIT ligands are highly
expressed in metastatic melanoma and TIGIT and PD-1
blockade increases the proliferation, cytokine production,
and degranulation of both tumour antigen-specific CD8+
T cells and CD8+ TILs in the presence of TIGIT
ligand-expressing cells. CD8+ TILs exhibited downregula-
tion of the costimulatory molecule CD226, which com-
petes with TIGIT for the same ligand, supporting a
TIGIT/CD226 imbalance in metastatic melanoma [18].
TIGIT
Exhausted 
CD8 TILs
CD8
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PD-1
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Fig. 1 Therapeutic strategies to target tumour-intrinsic and tumour-extrinsic mechanisms driving anti-tumour T cell dysfunction
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Dual PD-1/TIGIT blockade and dual PD-1/Tim-3
blockade are both potential strategies that are being
assessed in metastatic melanoma. TSR-022 (Tesaro), an
anti-TIM-3 monoclonal antibody, is being assessed alone
and in combination with an anti-PD-1 antibody in a
first-in-man dose escalation and cohort expansion phase
I study of patients with advanced solid tumours
(NCT02817633). Similarly, the anti-TIGIT antibody
BMS 9862017 is being investigated in a phase I/IIa
first-in-human study alone and in combination with
anti-PD-1 nivolumab in advanced solid tumours
(NCT02913313).
Therapeutic strategies that target tumour-extrinsic
mechanisms driving anti-tumour T cell dysfunction are
also being explored. One such example is faecal micro-
biota transplant (FMT). Gut microbiota from melanoma
patients who respond to PD-1 inhibition have higher
alpha-diversity and increased number of certain bacterial
commensals as compared to PD-1 non-responders. In
addition, FMT obtained from PD-1 responder melanoma
patients appeared to convert PD-1 refractory mice with
melanoma into PD-1 responders. A phase II feasibility
study of FMT in PD-1 resistant melanoma is planned at
the University of Pittsburgh to test the capability of the
gut microbiome to modulate clinical responses to
anti-PD-1 pembrolizumab in PD-1 refractory melanoma
patients (NCT03341143).
The search for blood-based biomarkers to predict
immunotherapy outcomes
PD-1/PD-L1 expression, cytolytic activity, and muta-
tional load are positive and interdependent prognostic
features in melanoma and other tumours [19]. Bio-
markers for anti-PD-1/PD-L1 are required and
blood-based markers offer several advantages over
tissue-based markers, in that analysis may be easier
and safer to perform, and blood may be indicative of
the entire disease burden (Fig. 2). Blood samples are
also amenable to virtually every analysis platform and
allow ready access to normal samples for comparative
analysis.
Circulating factors are likely to represent what is hap-
pening in the tumour. Circulating tumour DNA
(ctDNA) isolated from plasma has been shown to reflect
the mutational status of glioblastoma, and extracellular
vesicles containing ctDNA, microRNA and proteins act
as reservoirs for biomarkers such as typical DNA muta-
tions, regulatory microRNAs and oncoproteins [20]. At
Massachusetts General Hospital, serial ctDNA BRAF
mutation has been shown to correlate with response/
progression in patients treated with anti-BRAF vemura-
fenib and high-dose interleukin (IL)-2. Also, serial
ctDNA mutation correlates with response/progression in
patients treated with immune checkpoint inhibitors.
Longitudinal assessment of ctDNA predicts response to
anti-PD-1 antibodies in metastatic melanoma [21].
Non-detection or loss of detection of ctDNA was associ-
ated with excellent outcomes. Mutational load and pos-
sibly copy number alterations also predict response to
immunotherapy; analysis of mutational load and copy
number gains/losses is feasible from ctDNA. Genetic al-
terations associated with anti-PD-1 inhibitor resistance
(e.g. B2M) are detectable in ctDNA using ultra-low pass
whole genome sequencing and droplet digital polymer-
ase chain reaction (ddPCR) [22].
Exosomes represent another potential biomarker
source. Exosomes are extracellular vesicles that express
a sub-proteome of the cell and encapsulate mRNA that
can be transferred to other cells to modulate the recipi-
ents’ transcriptome [23]. Concordance in patient tu-
mours has shown enrichment for immune pathways in
patient plasma exosomes.
Circulating tumour cells (CTCs), exosomal RNA and
serum protein profile also represent potential
blood-based biomarkers for patients treated with
anti-PD-1 therapy. New technologies and novel plat-
forms are available to perform these broad and poten-
tially high-impact analyses and the next steps are
individual and cross-validation of these approaches.
Advantages of blood analysis
• Accessibility / safety
• Serial sampling is much easier
• Blood may be reflective of entire disease 
burden (heterogeneity)
• Amenable to analysis to virtually every 
platform of testing (flow cytometry, ELISA, 
mass spectometry, nucleic acid sequencing, 
etc.)
• Ready access to normal samples for 
comparative analysis
Advantages of tissue analysis
• Gold standard
• Sample is enriched for tumor 
– As opposed to blood which has other shed 
elements competing with tumor signal
– More amenable to nucleic acid sequencing 
(WES/WGS, RNA sequencing) 
• The tumor microenvironment is present and 
evaluable for physical interaction (IHC, IF, etc.)
Fig. 2 Blood-based biomarker development: blood versus tissue samples
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Genomics and immunotherapy in lung cancer:
tumour mutation burden, mutations affecting
antigen presentation, immune recognition, and
genome integrity
A wide range of tumour and immune biomarkers are be-
ing evaluated to predict better outcomes to immuno-
therapy (Fig. 3). High tumour mutation burden (TMB)
may influence the immune-mediated anti-tumour re-
sponse, meaning tumours with high TMB such as lung
cancer are a rational target for treatment with immuno-
therapy. Studies have suggested that TMB may be a pre-
dictive biomarker for immunotherapy agents [16, 24]. In
the CheckMate-026 trial, first-line nivolumab was not
associated with a significant improvement in
progression-free survival (PFS) or OS compared with
chemotherapy among patients with previously untreated
stage IV or recurrent PD-L1-positive NSCLC [25]. How-
ever, in patients with a high TMB, response rate was
higher with nivolumab and median PFS was prolonged
(9.7 vs. 5.8 months; hazard ratio [HR] for disease pro-
gression or death, 0.62; 95% CI: 0.38–1.00). There was
no significant association between TMB and PD-L1
tumour expression level but the highest response rate
was seen in patients with both high TMB and PD-L1 ex-
pression ≥50%.
Blood-based TMB can also be used as a biomarker to
predict clinical efficacy of anti-PD-L1, atezolizumab.
Data from the OAK and POPLAR trials of atezolizumab
as second-line treatment of NSCLC reported improved
PFS and OS versus docetaxel observed at a range of
blood TMB cutpoints [26].
Whole exome DNA sequencing and copy number
array data showed a landscape of significant alterations
to genes and pathways responsible for maintaining DNA
integrity in NSCLC. Tumours with nonsense mutations,
indels, or homozygous deletions in the FANCE or
MLH1 genes have significantly higher TMB [27]. Smok-
ing was not a sufficient substitute biomarker for TMB in
NSCLC, although DNA polymerase and mismatch exci-
sion repair pathway inactivation is enriched in
smoking-sensitive NSCLC.
Comprehensive genomic analysis of tumours and hosts
should lead to new insights into the host-tumour inter-
action, new biomarkers for selection of patients, and po-
tentially new therapeutic approaches. This will require
the collection of biospecimens and intensive, rational,
scientific analysis of specimens before and during
treatment.
Immunotherapy for advanced NSCLC: state of the
art
Several PD-1/PD-L1 inhibitors are approved or under
development for the treatment of NSCLC. In the phase
II ATLANTIC study in heavily pre-treated patients with
locally advanced or metastatic NSCLC, overall response
rate (ORR) with anti-PD-L1 durvalumab was 7.5% (95%
CI: 3.1–14.5) in patients with PD-L1 expression <25%
and 16.4% (95% CI:10.8–23.5) in patients with PD-L1
expression ≥25% [28]. An ORR of 30.9% (95% CI:
20.2–43.3) was observed in patients with PD-L1 ex-
pression ≥90%. Durvalumab showed a manageable
safety and tolerability profile, with most adverse
Adapted from Blank et al., 2016, Science.
. 2016;352:658-660.
CTLA4=cytotoxic T-lymphocyte antigen 4; I-O=immuno-oncology; IDO=indoleamine-2,3 dioxygenase; IFN=interferon; LAG-
3=lymphocyte activation gene-3; MDSCs=myeloid-derived suppressor cells; MSI-High=microsatellite instability high; PD-
1=programmed death receptor-1; PD-L1=programmed death ligand 1; TMB=tumor mutational burden; Treg=regulatory T 
cell.
Tumor Immune Suppression
• Biomarkers that identify tumor 
immune system evasion beyond 
PD-1/CTLA-4 to inform new 
immunotherapy targets and 
rational combinations
Examples:
• Tregs, MDSCs, IDO, LAG-3
Tumor Antigens
• Biomarkers indicative of 
hypermutation and neo-antigens 
may predict response to 
immunotherapy
Examples:
• TMB, MSI-high, neo-antigens
Inflamed Tumor 
Microenvironment
• Biomarkers (intra- or peri-tumoral) 
indicative of an inflamed phenotype 
may predict response 
to immunotherapy
Examples:
• PD-L1, inflammatory signatures 
(IFN-gamma)
Host Environment
• Biomarkers which characterize the 
host environment, beyond tumor 
microenvironment, may predict 
response immunotherapy
Examples:
• Microbiome, germline genetics
Fig. 3 Tumour and Immune biomarkers being evaluated to predict better outcomes to immunotherapy
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events low-grade and resolved with treatment delay
and/or immunosuppressive interventions. However, in
the phase III MYSTIC trial (NCT02453282), the com-
bination of first-line treatment with durvalumab and
tremelimumab in previously untreated NSCLC pa-
tients did not meet the primary endpoint of improved
PFS compared to standard of care in patients with
≥25% PD-L1 tumour expression (www.ascopost.com/
News/57874). Moreover, durvalumab monotherapy did
not show a PFS benefit over standard of care. Impres-
sive results have been obtained with durvalumab in
locally advanced disease in the PACIFIC trial
(NCT02125461) regardless of PD-1 expression. After
induction chemotherapy, patients receiving concurrent
chemo-radiotherapy were randomized to durvalumab
maintenance (n=476) or placebo (n=237) for up to 12
months. The primary study endpoint was reached
with a median PFS of 16.8 months for durvalumab
and 5.6 months for placebo arms (HR 0.52) [29].
In the OAK study, 1225 patients with previously
treated NSCLC were stratified according to PD-L1 sta-
tus, number of prior chemotherapy regimens and hist-
ology before being randomised to anti-PD-L1
atezolizumab 1200 mg or docetaxel 75 mg/m2 every 3
weeks [30]. In a preliminary analysis of data from 850
patients, there was a 27% improvement in OS in the ate-
zolizumab group compared with docetaxel (p=0.0003),
regardless of PD-L1 expression levels and including pa-
tients with PD-L1 expression <1%. When patients were
stratified according to their PD-L1 expression level, OS
was 59% greater among patients in the highest tertile of
PD-L1 expression with atezolizumab compared with do-
cetaxel (p<0.0001). However, even in patients with no
PD-L1 expression, there was a significant 25% improve-
ment in OS with atezolizumab compared to docetaxel.
Improvements in OS were similar in patients with squa-
mous and non-squamous histology. Atezolizumab was well
tolerated with a favourable safety profile. Atezolizumab is
currently being assessed as first-line monotherapy or com-
bined with chemotherapy in several trials in patients with
squamous or non-squamous NSCLC. It has been reported
that a phase III trial atezolizumab combined with bevacizu-
mab plus chemotherapy met its primary endpoint of PFS
versus bevacizumab plus chemotherapy as first-line therapy
of patients with non-squamous NSCLC (https://www.roche.
com/media/store/releases/med-cor-2017-12-07.htm).
The PD-1 inhibitors pembrolizumab and nivolumab
have both shown efficacy in NSCLC. In the
KEYNOTE-010 trial, pembrolizumab prolonged OS and
had a favourable benefit-to-risk profile in patients with
previously treated PD-L1-positive advanced NSCLC
[31], while in KEYNOTE-024, pembrolizumab was su-
perior to chemotherapy as first-line therapy for advanced
NSCLC with PD-L1 tumour expression ≥50% [32]. The
combination of pembrolizumab with carboplatin and
pemetrexed has also been shown to be an effective
and tolerable first-line treatment option for patients
with advanced non-squamous NSCLC, with longer
PFS versus carboplatin and pemetrexed in a phase II
randomized trial (HR 0.49, 95% CI: 0.29–0.83,
p=0.0035) [33]. First-line pembrolizumab in combin-
ation with pemetrexed and either cisplatin or carbo-
platin is also being assessed in non-squamous NSCLC
in the phase III KEYNOTE-189 trial (NCT02578680).
Recently the manufacturer reported that the study
met its primary endpoints with pembrolizumab com-
bined with chemotherapy improving PFS and OS com-
pared to chemotherapy alone (http://investors.merck.com/
news/press-release-details/2018/Mercks-KEYTRUDAR-
pembrolizumab). Clinical trials have also suggested that
nivolumab provides long-term clinical benefit and a
favourable tolerability profile compared with docetaxel in
previously-treated patients with advanced NSCLC [34]. In
the CheckMate-026 trial, nivolumab was not associated
with significantly improved PFS or OS when compared
with platinum-based chemotherapy in patients with previ-
ously untreated NSCLC with a PD-L1 expression level ≥5%
[25]. However, nivolumab improved ORR and PFS com-
pared with platinum doublet chemotherapy in patients with
high TMB. The results of a large phase III randomized trial
(CheckMate 227; NCT02477826) assessing the role of nivo-
lumab as a single agent, combined with chemotherapy or
with ipilimumab in a first-line setting are pending.
Immunotherapy for head and neck cancer
Immune checkpoint therapy, specifically PD-1 pathway
blockade, improves survival in patients with metastatic
squamous cell carcinoma of the head and neck
(SCCHN) [35]. However, PD-1 monotherapy in SCCHN
seems associated with relatively lower ORRs compared
with other indications, such as NSCLC or melanoma,
and many patients fail to respond. Cetuximab, an IgG1
isotype, is a standard of care treatment for locally ad-
vanced and recurrent and/or metastatic SCCHN. In
addition to EGFR inhibition, cetuximab mediates clinic-
ally relevant antibody-dependent cell-mediated cytotox-
icity (ADCC) and other immune activity in the
intratumoural space [36]. Cetuximab can prime the im-
mune system for checkpoint inhibitor therapy by recruit-
ing cytotoxic cell effectors of both the innate and
adaptive immune systems to the tumour [36]. However,
associated negative feedback loops lead to immune
checkpoint-mediated immunosuppression. Therefore,
co-targeting of these immunosuppressive processes has
the potential to improve patient outcomes, given the po-
tential synergy between the different mechanisms of ac-
tion of cetuximab and immunotherapy.
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In the CheckMate-141 study, nivolumab resulted in
significantly prolonged OS versus investigators’ choice of
therapy (methotrexate, docetaxel, or cetuximab) in pa-
tients with platinum-refractory SCCHN. Nivolumab im-
proved OS versus investigators’ choice regardless of
prior cetuximab, although improvement was greater in
patients without previous cetuximab treatment [37].
This may relate to cross-presentation of tumour antigens
by DCs to T cells.
Several other trials of cetuximab and immune check-
point inhibition combination therapy in SCCHN are on-
going. Cetuximab-mediated immune action drives
crosstalk with a variety of immune cell types and pro-
cesses, and therefore it holds the potential for combin-
ation with other immunotherapy agents, including
motolimod, a TLR-8 agonist.
Contrasts between immunotherapy for renal
carcinoma and melanoma
Renal cell carcinoma (RCC) and melanoma have long
been recognised as immune-responsive, with spontan-
eous remissions sometimes observed in both diseases.
Cytokine-based treatment (e.g., interferon [IFN], IL-2)
only induced durable responses in a small fraction of
both metastatic RCC and melanoma patients ([38, 39]
However, checkpoint inhibitors targeting CTLA-4 and
PD-1 have achieved durable responses in patients who
were refractory to other therapies. In the
CheckMate-025 trial that compared nivolumab with
everolimus, the primary endpoint was met early on, with
the nivolumab group achieving median OS of 25 months
(95% CI: 21.8-not estimable) compared with 19.6
months (95% CI: 17.6–23.1 months) with everolimus
[40]. Response rates in melanoma with single agent
anti-PD1 inhibitors are higher than those seen in RCC.
Combination immunotherapy will become a new
standard of care in RCC as it has in melanoma. In the
CheckMate-214 trial, combined nivolumab plus ipilimu-
mab followed by nivolumab monotherapy is being com-
pared with sunitinib, a multi-targeted receptor tyrosine
kinase inhibitor. At a minimum 17.5 months follow-up,
confirmed ORR in intermediate/poor risk patients was
42% (9.4% CR) with nivolumab plus ipilimumab com-
pared with 27% (1.2% complete responses [CR]) with su-
nitinib (p<0.0001) and median PFS was 11.6 versus 8.4
months (HR 0.82, p=0.0331) [41]. Interestingly no im-
provements have so far been seen in ORR or PFS in pa-
tients with a favourable risk. Low-risk, good prognosis
metastatic RCC therefore appears to derive less benefit
from combination immunotherapy than the equivalent
group of melanoma patients. Further follow up is re-
quired to establish whether this is a real observation or
whether a durable advantage with immunotherapy in this
group emerges. A lower dose of ipilimumab (1 mg/kg)
was administered in the RCC combination which is likely
to be the reason for the good tolerability profile in RCC.
Despite the lower ipilimumab dose, the activity of combin-
ation therapy in RCC is significantly greater than single
agent PD1 blockade (cross-study comparison) suggesting
a synergistic rather than additive effect, probably contrib-
uting to the contrasts between immunotherapy for RCC
and melanoma.
Dissecting the tumour microenvironment in renal
cancer
RCC of clear-cell type (ccRCC), the most common type,
has traditionally been considered an immune responsive
tumour along with melanoma. Unlike melanoma, how-
ever, the mutation burden of ccRCC is modest (1–2 mu-
tations per Mb). Immune responsiveness has been
attributed to more antigenic mutations, reactivation of
endogenous retroviruses, and a high level of inflamma-
tion. In regards inflammation, gene expression analyses
have shown that ccRCC is a particularly inflamed
tumour compared to other tumour types. Notably, sev-
eral indicators of inflammation such as thrombocytosis,
neutrophilia and anaemia are established prognostic fac-
tors in metastatic ccRCC. Furthermore, there appears to
be a relationship between these prognostic variables and
response to immunotherapy. Specifically, it has been
shown in a phase 3 trial (Checkmate-214) that ipilimu-
mab/nivolumab is superior to sunitinib in patients with
intermediate and poor risk disease (with at least one risk
factor including the aforementioned plus hypercalcemia,
poor performance status and time to systemic therapy of
less than one year), but not in those in a good risk group
[41]. Thus, understanding how ccRCC induces inflam-
mation may help identify determinants of immune
responsiveness.
To understand how ccRCC induces inflammation, we
sought to probe the relationship between the tumour
and the tumour microenvironment (TME). Different ap-
proaches have been previously explored including both
experimental and in silico approaches to evaluate the
TME. Experimental approaches have focused on single
cell analyses using mass cytometry or single cell RNA
sequencing [42, 43]. In silico approaches have attempted
to deconvolute the bulk tumour gene expression signa-
ture to distinguish contributions from the tumour cells
versus its microenvironment [44]. By using previously
characterized cell type-specific gene expression signa-
tures, their presence in the TME can be ascertained.
To explore the ccRCC TME, we have taken a novel
approach. To separate from bulk tumour gene expres-
sion the tumour and TME components, we leveraged
tumorgrafts (TGs or PDX models). Over the years, we
have implanted kidney tumour samples from over 1000
patients orthotopically in mice. The most aggressive of
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these samples will grow to form large tumours within a
few weeks. These tumours are made up of human
tumour cells, but the stroma is from the mouse host
[45–47]. We reasoned that by subtracting the human
tumorgraft signature from the corresponding original
patient’s tumour, we would be left with a gene expres-
sion signature corresponding to the TME. This signature
we refer to as the empiric tumour microenvironment
signature or eTME. We applied this approach to 35
RCCs, including 29 ccRCCs, for which we performed
RNAseq. We subtracted from the patient bulk tumour
RNAseq signature, the corresponding TG signature (hu-
man genes only) and the signature from the particular
patient normal kidney. To accomplish this, we developed
an algorithm, dissecting heterogeneous tumours
(DisHet), which is based on a Bayesian approach. DisHet
identified over 2000 genes expressed at ≥3-fold higher
levels in the TME than in RCC, including >900 genes
expressed at >20 fold higher levels [unpublished data].
The majority of these genes have not been previously as-
sociated with the RCC TME. Interestingly, the eTME
signature was able to resolve different RCC histologies
to an even greater extent than traditional bulk gene ex-
pression signatures. Furthermore, we identified an in-
flamed gene expression signature that was associated
with anaemia, thrombocytosis and poor patient survival.
What role for immunotherapy in the treatment of
hepatocellular carcinoma?
The advent of sorafenib improved survival outcomes
among patients with HCC. Recent studies have demon-
strated the efficacy of new targeted agents; first-line len-
vatinib (a tyrosine kinase inhibitor) has been shown to
be non-inferior to sorafenib [48], and regorafenib (an-
other tyrosine kinase inhibitor) is used after sorafenib
failure [49]. The potential role of immune checkpoint in-
hibitors is also a focus of attention. HCC is typically an
inflammation-associated cancer and can be immuno-
genic. Hepatitis C (HCV) and hepatitis B (HBV) infec-
tion have been associated with upregulation of PD-1,
and upregulation of PD-1 and PD-L1 in HCC is associ-
ated with poor outcomes. PD-1 blockade with nivolu-
mab may boost host immunity against HCC and
improve clinical outcomes.
In the phase I/II CheckMate-040 trial in patients with
advanced HCC with or without HCV or HBV, nivolu-
mab had a manageable safety profile with no maximum
tolerated dose reached in a dose escalation phase [50].
In the dose expansion phase, nivolumab 3 mg/kg re-
sulted in an ORR of 20% (95% CI: 15–26), with 18% par-
tial responses (PR) and 1% CR. Disease control rate was
64% (95% CI: 58–71) and OS at 9 months was 74% (95%
CI: 67–79). Response was not correlated with tumour
PD-L1 expression. Further trials of anti-PD agents in
HCC are ongoing. These include nivolumab versus sorafe-
nib as first-line treatment in patients (NCT02576509), and
second-line pembrolizumab compared with best support-
ive care (NCT02702401).
Dendritic cell vaccine combinations for melanoma
DCs play a critical role in promoting an immune re-
sponse against antigens, including TAAs. DC are capable
of boosting a memory T cell response and are effective
initiators of naïve T cell responses. DC vaccines were
originally considered a stand-alone therapeutic approach
to promote regression of tumours. However, with the
advent of immune checkpoint inhibitors and data sup-
porting the need for a pre-existing immune response in
the tumour for successful checkpoint blockade response,
vaccines may have a role in promoting anti-tumour im-
mune responses in patients who lack spontaneous
immunity.
Although the identification of an optimal antigen is
important for directing anti-tumour immunity to the
tumour, the spread of the immune response from one
antigen to another antigen expressed in the same tissue
(‘determinant’ [or epitope or antigen] spreading) has also
been associated with superior clinical outcome [51].
AdVTMM2, an E1/E3-deleted adenovirus encoding
three full length melanoma antigens (tyrosinase,
MART-1 and MAGE-A6), expresses mRNA and protein
for all antigens, and AdVTMM-transduced DCs activate
both CD8+ and CD4+ T cells that recognise melanoma
tumour cells more efficiently than single antigen
adenovirus-DC vaccines [51]. Addition of physiological
levels of IFN-α can further amplifies melanoma
antigen-specific T cell activation in vitro. NK cells can
also be recruited by AdV-transduced DC via IL-8 and
IFN-γ-inducible protein-10 (IP-10), and show cytotoxic
activity. These data formed the hypotheses tested in a re-
cent clinical trial.
Melanoma patients were found to have decreased ex-
pression of co-stimulatory molecules (e.g. ICOSL,
OX40L) with AdVTMM2 DC compared to healthy do-
nors, while both melanoma patients and healthy donors
had increased expression of co-inhibitory molecules
(TIM3L, PD-L1, PD-L2, CTLA-4) in matured compared
with immature DC [unpublished data]. DC vaccination
successfully increased the frequency of functional
melanoma-specific CD8 and CD4 T cells, and approxi-
mately 7–10% of tumour-specific CD8 cells were
CTLA-4 positive while 20–28% were PD-1 positive.
Melanoma patient-derived AdVTMM2 DC were also in-
ferior at producing chemokines and produce more im-
munosuppressive cytokines compared to DC vaccines
made from healthy donor cells. Addition of one month
of high dose systemic IFN-α did not improve T cell re-
sponses or clinical responses. IFN-α therapy did increase
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expression of chemokine receptors on the three NK cell
subsets and increases circulating NK cell lytic ability.
These data support clinical testing of new rational com-
binations with antigen loaded DC, such as with check-
point blockade.
New developments in oncolytic virus
immunotherapy
Oncolytic viruses mediate anti-tumour activity via mul-
tiple mechanisms of action and are uniquely positioned to
serve as the foundation for combination immunotherapy
regimens. Herpes simplex virus type-1 (HSV-1) mediates
immunogenic oncolysis, has a broad host cell range, in-
duces innate and adaptive immune responses that can en-
code eukaryotic transgenes, is genetically stable and
replication competent, and is easy to attenuate [52]. Tali-
mogene laherparepvec (T-VEC) is an intralesional oncoly-
tic virus therapy based on a modified HSV-1. T-VEC
selectively targets tumour cells, causing regression in
injected lesions and inducing immunologic responses that
mediate regression at uninjected/distant sites. T-VEC has
shown synergy with ipilimumab and pembrolizumab in
melanoma, without additional toxicity [53, 54].
The next generation of HSV-1 oncolytic viruses are
now being developed. These are based on a very potent
underlying HSV strain with an additional increase in dir-
ect tumour cell killing and viral spread through expres-
sion of a fusogenic protein that provides a 10–100-fold
improvement in lytic activity in vitro and highly im-
munogenic cell death and release of tumour
antigen-containing exosomes. Expression of Gibbon Ape
Leukaemia virus (GALV) provides enhanced potency in
human tumour cell lines, promoting virus distribution
within the tumour microenvironment while GM-CSF ex-
pression stimulates DC activity in the tumour [unpub-
lished data]. This platform (RP1) can then be used to
deliver additional potent immune stimulatory proteins
directly to the tumour, focusing on pathways where sys-
temic engagement is sub-optimal. RP1 has been shown
to reduce large injected and uninjected rat 9L glioma tu-
mours in immune-competent rats and a phase I/II clin-
ical trial of RP1 alone and in combination with
checkpoint blockade across several tumour types has
been initiated. RP2 and RP3 are derivatives of RP1 that
express additional proteins. RP2 expresses an
anti-CTLA-4 antibody-like molecule and RP3 addition-
ally expresses optimised immune co-stimulatory path-
way ligands. These therapeutics provide targeted delivery
to the sites of immune response initiation in the tumour
and draining lymph nodes with the goal of focusing sys-
temic immune-based efficacy on tumours and limiting
off-target toxicity.
An important consideration is the need for biomarkers
for oncolytic virus immunotherapy. Oncolytic viruses
are able to induce T cell recruitment and activation and
increase PD-L1 expression within the tumour micro-
environment. For example, T-VEC and pembrolizumab
increased CD8+ T cell density and PD-L1 in responding
lesions [54]. T-VEC and pembrolizumab also induced
type 1 IFN and PD-L1 expression [54]. Oncolytic viruses
can also result in expanded neoantigen-specific CD8+ T
cells in PD-1 refractory tumour cells. Stimulator of IFN
genes (STING) is an essential molecule that controls the
production of host defence proteins, including type I
IFNs and proinflammatory cytokines [55]. STING ex-
pression correlates with tumour cell resistance to T-VEC
infection [56]. STING transduction in STING-lo SK-Mel
2 cell lines inhibits lytic activity in vitro and STING
knockout via CRSP/Cas9 restores lytic activity in resist-
ant LOXIMVI melanoma cell lines. Anti-viral machinery
status may thus be a potential biomarker for response.
Building the next generation of highly potent
adoptive cancer immunotherapies
Progress in gene engineering has resulted in an exponen-
tial growth in the number of adoptive cell transfer (ACT)
trials [57]. Adoptive transfer of receptor-engineered T cells
has produced impressive results in treating patients with
B cell leukaemia and lymphoma. However, there is a need
to enhance the efficacy of adoptive immunotherapies for
the treatment of advanced solid cancers. Across clinical
trials, there has been an association between T cell expan-
sion and persistence and tumour regression in patients
with hematologic and solid cancers receiving ACT. Thus,
T cell persistence has been one of the few consistent bio-
markers of response across the majority of ACT clinical
trials [58, 59]. Thus, in theory, disruption of pathways that
impair T cell persistence could result in enhanced
anti-tumour efficacy following ACT. Identifying poten-
tially actionable factors that limit the intrinsic capacity of
T cells to expand and persist could improve outcomes and
is not an approach that is addressed with current thera-
peutic options.
The majority of human cancers were found to overex-
press the gene encoding Fas-ligand (FasL) relative to
normal tissues. T cells used for clinical ACT are skewed
towards antigen experienced subsets, all of which consti-
tutively co-express Fas/CD95 [60]. Consequently, adop-
tively transferred T cells are poised to undergo apoptosis
upon entering the tumour microenvironment.
FasL-induced apoptosis requires both Fas oligomerisa-
tion and FADD recruitment. Overexpression of a Fas
death domain variant prevents Fas crosslinking. T cells
engineered with Fas mutants are expressed 5–10-fold
higher compared with wild-type Fas, preventing
FasL-induced apoptosis in a dominant negative fashion.
T cells engineered with a Fas dominant negative receptor
(DNR) exhibited superior in vivo persistence and show
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superior anti-tumour efficacy in animal models. Fas
DNRs block Fas-induced AKT pathway activation and
limit AKT-induced T cell differentiation [61]. CD8+ T
cell differentiation status is highly correlated with
anti-tumour efficacy in mice. Normalising for T cell dif-
ferentiation does not compromise the in vivo
anti-tumour efficacy of Fas DNR modified T cells.
Germline loss of Fas function can result in an auto-
immune lymphoproliferative syndrome (ALPS); however,
mice receiving ACT of Fas modified T cells do not de-
velop an acquired ALPS syndrome and human T cells
modified with Fas DNR are protected from FasL induced
T cell death. In summary, T cells engineered to intrinsic-
ally resist FasL-induced cell death have superior
anti-tumour efficacy and represent a potentially univer-
sal strategy to enhance adoptive immunotherapy for ad-
vanced solid cancers.
A novel human memory CD4 T cell subset with
durable anti-tumour properties
Although CD8+ T cells have shown clinical promise, hu-
man CD4+ T cell subsets that exhibit properties of stem-
ness and natural migration to the tumour have yet to be
identified. Previous studies on CD4+ T cells has shown
that they polarize to a type 17 phenotype (Th17) that ex-
hibits stem cell-like memory qualities and yield greater
tumour regression and persistence in vivo than other T
helper subsets. The hypothesis that human Th17 cells
are most effective has prompted investigations to deter-
mine if genetically redirected human IL-17+ T cells with
antigen receptors can mediate superior regression of hu-
man tumours than unpolarised redirected cells.
Co-stimulation has also been reported to impact the
antitumor fate of Th17 cells. ICOS is a CD28 family
costimulatory molecule that is structurally and function-
ally related to CD28 and CTLA-4. CD28 but not ICOS
induces IL-2 and combining CD28 and ICOS augments
the effector function of murine T cells. ICOS has been
demonstrated to promote robust Th17-mediated im-
munity in melanoma and in mesothelioma [62, 63].
Interestingly, more recent investigations reveal that
ICOS can promote T cells that have high expression of
CD26 on their cell surface (CD26high) and which pro-
duce abundant IL-17 [unpublished data].
CD26 is an enzymatic, multifunctional protein shown
to have a role in T cell co-stimulation as well as the
binding of extracellular matrix proteins/adenosine deam-
inase (Fig. 4). CD26 expression correlates with specific
CD4+ T cell subsets with distinct immunological proper-
ties. CD26neg T cells possess a regulatory phenotype, but
CD26int T cells are mainly naïve and CD26high T cells ap-
pear terminally differentiated and exhausted. Despite
this, CD26high T cells persist in and regress multiple solid
tumours following ACT. Further analysis revealed that
CD26high cells have a rich chemokine receptor profile,
profound cytotoxicity, resistance to apoptosis, and en-
hanced stemness [64].
In conclusion, CD26high T cells have a mixed Th1/
Th17/Th22 phenotype, yet are unique, are highly multi-
functional and exert greater cytotoxicity and control
tumour growth both in vitro and in vivo. These
CD26high
T cell
RANTES, CXCL12, etc.
Adenosine
Inosine A2AR
ADA
Cav-1
T cell costimulation Chemokine cleavage
ECM binding Adenosine conversion
Tumor
CD86
Fibronectin
Collagen
APC
Fig. 4 CD26 is an enzymatic, multifunctional protein
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characteristics mean CD26high T cells have a natural cap-
acity to traffic to, regress and survive in solid tumours,
properties that may help to improve cancer immuno-
therapy. This new finding is exciting because it means
that CD26 could be targeted to augment adoptive T cell
transfer therapy as well as other forms of cancer im-
munotherapy, including checkpoint inhibitors and can-
cer vaccines.
Chimeric-antigen receptor T cells for haematological
malignancies: building upon CAR-T19
Anti-CD19 chimeric-antigen receptor T cells (CART19)
have shown high response rates and durable remissions
in relapsed/refractory(r/r) B-cell acute lymphoblastic
leukaemia (B-ALL) and non-Hodgkin lymphoma (NHL)
[65]. Thanks to this impressive clinical activity two
CART19 products, CTL019 (Kymriah®, Novartis) and
KTE-19 (Yescarta®, Kite Pharma/Gilead) were recently
approved by the US Food and Drug Administration for
the treatment of refractory or relapsed paediatric and
young-adult B-ALL or refractory or relapsed adult dif-
fuse large-B cell lymphoma, respectively. However, des-
pite the high response rates after CART19
immunotherapy, a subset of patients still relapses and, in
particular in B-ALL, the majority of the relapses are
caused by the loss of CD19 on leukemic cells [66]. Sev-
eral mechanisms of CD19-targeted therapy resistance
have been described, including convergence of acquired
mutations of the CD19 gene, alternative CD19 splicing
[67] and others [68, 69]. However, these known mecha-
nisms do not explain all cases of CD19-negative B-ALL
relapses. We recently reported [70] the case of a paediat-
ric B-ALL patient who relapsed 9 months after CTL019
with a CD19-negative leukaemia. Unexpectedly, 100% of
leukemic blasts were found to aberrantly express the
CAR19 protein on the surface. Our data show that a sin-
gle leukemic cell was accidentally transduced with
CAR19, survived the 10-day manufacturing process and,
upon reinfusion into the patient, was solely responsible
for the relapse 9 months later. The relapsed clone was
resistant to killing by CART19 cells in a xenograft model
yet retained sensitivity to anti-CD22 CAR-T cells. More-
over, as the high expression of the CAR19 in leukemic
cells and its absence from normal tissues make it an
ideal engineered tumour target, we developed
anti-CAR19 CAR T cells with the goal of specifically tar-
geting CAR19+ B-ALL [71]. We proved that
anti-CAR19 CART can efficiently target CAR19+ leukae-
mia in xenograft models, thereby presenting an oppor-
tunity for specific targeting without off-target toxicity. In
conclusion, highly targeted and potent immunotherapies
can lead to novel specific relapse mechanisms and only a
deep understanding of the pathogenesis of these relapses
can drive the generation of new tailored treatments.
System immunology to decipher the tumour
microenvironment
Systems biology approaches have facilitated analysis of
the complex interaction between tumours and the
host-immune response and have allowed the defin-
ition of the immune contexture (i.e. the type, density
and location of cytotoxic and memory T cells within
the tumour), which can be a strong prognostic
marker when quantified by the Immunoscore [72, 73].
Tumour progression, invasion and recurrence are
dependent on the immune contexture and Immuno-
score and survival is strongly influenced by
pre-existing immunity. The tumour microenvironment
evolves with tumour progression, with the immune
infiltrate composition changing at each tumour stage
and particular cells having a major impact on sur-
vival. In an analysis of the spatiotemporal dynamics
of 28 different immune cell types infiltrating tumours,
T follicular helper and innate cells increased, whereas
most T cell densities decreased with tumour progres-
sion [74]. The number of B cells increased at a late
stage and showed a dual effect on recurrence and
progression. The genetic features of the tumour contribute
to shaping the tumour escape mechanisms. In hypermutated
tumours, immune-inhibitors are upregulated and immuno-
suppressive cells are depleted, while in non-hypermutated
tumours, immune-inhibitors are downregulated but im-
munosuppressive cells are enriched [75].
The tumour microenvironment and immune con-
texture are critical determinants of dissemination to
distant metastases [76]. However, a key question is
whether an immune escape occurs at the metastatic
stage. In a study to assess how the metastatic im-
mune landscape impacts response to treatment and
patients’ outcome, Immunoscore was analysed after
complete curative resection of multiple metastases at
different sites (n = 441) in patients with colorectal
cancer [77]. Response to treatment and prolonged
survival were significantly associated with
high-immune densities quantified into the least
immune-infiltrated metastasis. Tumours with a
pathological response had higher densities of immune
cells (CD3, CD8, CD20) and patients who responded
to neoadjuvant treatment had higher densities of im-
mune cells (CD3, CD8, CD20, CD45RO, FOXP3).
Immunoscore more than tumour regression predicted
PFS and OS and surpassed all known variables asso-
ciated with outcome in stage IV disease. High Immu-
noscore within metastases predicted prolonged
survival and the least regressing metastasis had the
lowest Immunoscore. Immunoscore also predicted
OS and long-term survival in patients with brain me-
tastases and was independent from established prog-
nostic parameters [78].
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Conclusions
The immunotherapy of cancer has made rapid and
major advances in recent years and is now recognised as
a critical element in the treatment of many cancer types.
Increased understanding of the complex interactions be-
tween tumours and the host immune response is leading
to the development of novel therapeutic strategies across
different cancers. In particular, research into a wide
range of different and potentially synergistic immuno-
therapy combinations is ongoing and may hopefully lead
to more durable responses for higher numbers of pa-
tients. The development and utilisation of effective bio-
markers to guide the use of immunotherapies is another
critical area for research and should help ensure that pa-
tients are treated with the most appropriate option.
Novel immuno-based therapeutic approaches have
already revolutionised cancer treatment and improved
long-term outcomes for many patients and insights from
ongoing and planned research should help to continue
this progress.
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